Idorsia names Srishti Gupta as CEO

10 June 2025

Swiss pharma company Idorsia (SIX: IDIA) today announced the appointment of Dr Srishti Gupta as chief executive (CEO), effective July 1, 2025.

The company said that Dr Gupta is uniquely placed to take the leadership of the company having served on the board of directors since 2021, gaining a deep understanding of the company, the people, the business, and Idorsia’s outstanding product and development portfolio.

Dr Gupta is a physician and seasoned leader in global health and biopharmaceutical innovation, with more than 20 years of experience advancing science-driven solutions across medicine, strategy, and healthcare systems. She has led high-impact teams and advised companies across therapeutic areas on portfolio development, business strategy, and patient access. Dr Gupta spent 18 years at McKinsey & Company as a senior leader in the pharmaceutical and global health practices. She has since served in leadership roles on the boards of biotechnology companies and global health partnerships, with a focus on translating cutting-edge science into meaningful patient impact.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK